Business Context and Reporting Period
This Form 8-K filing by Cara Therapeutics, Inc. (not Tvardi Therapeutics, Inc.) reports on the results of its Annual Meeting of Stockholders held on June 1, 2023. The company is incorporated in Delaware and trades on the Nasdaq Stock Market under the symbol CARA.
Key Financial Metrics
This filing is a current report regarding corporate governance events and does not contain financial performance data. There is no information provided regarding revenue, profit, cash flow, margins, debt, or liquidity in this document.
Material Changes and Voting Results
The filing details the outcomes of three proposals voted on by stockholders:
- Proposal 1 (Election of Directors): Martin Vogelbaum and Dr. Lisa von Moltke were elected to the Board of Directors until the 2026 Annual Meeting.
- Martin Vogelbaum: 28,082,224 votes For; 6,629,677 votes Withheld.
- Lisa von Moltke, M.D.: 32,087,634 votes For; 2,624,267 votes Withheld.
- Proposal 2 (Executive Compensation): Stockholders approved the compensation of Named Executive Officers on a non-binding advisory basis.
- Result: 26,928,795 votes For; 7,711,887 votes Against; 71,219 Abstentions.
- Proposal 3 (Auditor Ratification): Stockholders ratified the selection of Ernst & Young LLP as the independent registered public accounting firm for the year ending December 31, 2023.
- Result: 43,767,233 votes For; 179,748 votes Against; 66,965 Abstentions.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, financial guidance, outlook, or specific risk factors. It strictly reports the procedural outcomes of the shareholder vote.
Important Facts for Investors to Verify
- Verify the company name is Cara Therapeutics, Inc. (CARA), as the input metadata incorrectly referenced "Tvardi Therapeutics, Inc."
- Confirm the tenure of the newly elected directors (Martin Vogelbaum and Dr. Lisa von Moltke) extends through the 2026 Annual Meeting.
- Note that the "Say on Pay" vote (Proposal 2) received significant opposition, with approximately 22% of votes cast against the proposal.
- Review the Proxy Statement filed on April 20, 2023, for detailed descriptions of the proposals and executive compensation specifics.